Vestal Point Capital, LP 13D and 13G filings for Bicara Therapeutics Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 5:06 pm Purchase | 2026-03-31 | 13G | BICARA THERAPEUTICS INC BCAX | Vestal Point Capital, LP | 5,425,000 8.300% | 1,850,000 (+51.75%) | Filing |
| 2026-02-17 4:10 pm Sale | 2025-12-31 | 13G | BICARA THERAPEUTICS INC BCAX | Vestal Point Capital, LP | 3,575,000 6.500% | -1,425,000 (-28.50%) | Filing |
| 2025-08-14 3:57 pm Purchase | 2025-06-30 | 13G | BICARA THERAPEUTICS INC BCAX | Vestal Point Capital, LP | 5,000,000 9.200% | 2,231,025 (+80.57%) | Filing |
| 2025-05-15 4:13 pm Purchase | 2025-03-31 | 13G | BICARA THERAPEUTICS INC BCAX | Vestal Point Capital, LP | 2,768,975 5.100% | 2,768,975 (New Position) | Filing |